Prothrombin complex concentrate, Human


Thông tin thuốc gốc
Chỉ định và Liều dùng
Intravenous
Treatment and prophylaxis of haemorrhage
Adult: In patients with acquired coagulation factor deficiency: ≤100 kg: 25-50 IU/kg via slow injection not more than 8 mL/min; >100 kg: Max: 2,500-5,000 IU. Dosage is individualised based on INR level prior to treatment and the target INR (refer to detailed product guideline). In patients with congenital coagulation factor deficiency: Calculate required dosage based on severity of coagulation disorder, location and extent of haemorrhage and patient’s clinical condition following specific formula (refer to detailed product guideline).
Hướng dẫn pha thuốc
Reconstitute vial labelled as 500 IU or 1,000 IU with 20 mL or 40 mL sterile water for inj respectively, to a final concentration between 20-31 IU/mL. Gently swirl or rotate the vial to dissolve. Do not shake or agitate.
Chống chỉ định
Hypersensitivity to prothrombin complex and heparin. Active thrombosis, disseminated intravascular coagulation (DIC), history of heparin-induced thrombocytopenia (HIT), and immunoglobulin A (IgA) deficiency within the past 3 months.
Thận trọng
Patient with history of thromboembolic events (e.g. CHD, CVA, MI, TIA, unstable angina pectoris, severe peripheral vascular disease); simultaneous inhibitor deficiency, high risk of virus transmission. Hepatic impairment. Neonates, children. Pregnancy and lactation.
Phản ứng phụ
Significant: Anaphylactic reactions, hypotension, thromboembolic events (e.g. stroke, pulmonary embolism, DVT), increased body temperature. Rarely, anaphylaxis.
Blood and lymphatic system disorders: Anaemia.
Gastrointestinal disorders: Nausea, vomiting.
Musculoskeletal and connective tissue disorders: Chills.
Nervous system disorders: Headache.
Skin and subcutaneous tissue disorders: Urticaria.
IV/Parenteral: C
MonitoringParameters
Closely monitor vital signs, cardiac, and CNS status before and during the infusion. Assess prothrombin time/INR, aPTT, and clotting factor assays prior to, during, and after therapy. Watch out for signs and symptoms of thromboembolic events and excessive bleeding.
Tác dụng
Description: Prothrombin concentrate complex (PCC) is a factor IX preparation from human plasma containing variable amount of factor II, VII and X. It rapidly increases the plasma levels of the vitamin K-dependent coagulation factors and temporarily correct the coagulation defect in patient with deficiency of these factors.
Onset: Significant decline in INR: Within 10 minutes.
Duration: Approx 6-8 hours.
Pharmacokinetics:
Excretion: Elimination half-life: Factor II: 48-60 hours; factor VII: 1.5-6 hours; factor IX: 20-24 hours; factor X: 24-48 hours; protein C: 1.5-6 hours; protein S: 24-48 hours.
Bảo quản
Store between 2-25°C. Do not freeze. Protect from light.
Phân loại MIMS
Phân loại ATC
B02BD01 - coagulation factor IX, II, VII and X in combination ; Belongs to the class of blood coagulation factors. Used in the treatment of hemorrhage.
References
Anon. Prothrombin Complex Concentrate (Human). Lexicomp Online. Hudson, Ohio. Wolters Kluwer Clinical Drug Information, Inc. https://online.lexi.com. Accessed 14/06/2018.

Buckingham R (ed). Factor IX. Martindale: The Complete Drug Reference [online]. London. Pharmaceutical Press. https://www.medicinescomplete.com. Accessed 14/06/2018.

Joint Formulary Committee. Dried Prothrombin Complex. British National Formulary [online]. London. BMJ Group and Pharmaceutical Press. https://www.medicinescomplete.com. Accessed 14/06/2018.

Kcentra (CSL Behring GmbH). DailyMed. Source: U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/dailymed/. Accessed 14/06/2018.

Thông báo miễn trừ trách nhiệm: Thông tin này được MIMS biên soạn một cách độc lập dựa trên thông tin của Prothrombin complex concentrate, Human từ nhiều nguồn tài liệu tham khảo và được cung cấp chỉ cho mục đích tham khảo. Việc sử dụng điều trị và thông tin kê toa có thể khác nhau giữa các quốc gia. Vui lòng tham khảo thông tin sản phẩm trong MIMS để biết thông tin kê toa cụ thể đã qua phê duyệt ở quốc gia đó. Mặc dù đã rất nỗ lực để đảm bảo nội dung được chính xác nhưng MIMS sẽ không chịu trách nhiệm hoặc nghĩa vụ pháp lý cho bất kỳ yêu cầu bồi thường hay thiệt hại nào phát sinh do việc sử dụng hoặc sử dụng sai các thông tin ở đây, về nội dung thông tin hoặc về sự thiếu sót thông tin, hoặc về thông tin khác. © 2021 MIMS. Bản quyền thuộc về MIMS. Phát triển bởi MIMS.com
  • Kaskadil
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in